Government of **Western Australia**
Department of **Health**

Structured Administration and Supply Arrangement (SASA)

TITLE: **Administration of Buprenorphine Depot injection by pharmacists**

1. **Authority:**

   Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

2. **Scope:**

   This SASA authorises a registered pharmacist trained in the Community Program for Opioid Pharmacotherapy (CPOP) to administer buprenorphine depot injections, when requested by the CPOP prescriber and patient, subject to the criteria and conditions below.

3. **Criteria:**

   This SASA authorises the actions specified in the table below.

Practitioner:	Registered pharmacist who has completed approved training in accordance with Appendix 1
Practice setting:	At a registered pharmacy in Western Australia that complies with Appendix 2
Approved activity:	Administration
Approved medicines:	Buprenorphine depot injection
Medical conditions:	Opioid substitution therapy for the management of opioid dependence.

4. **Conditions:**

   The administration of approved medicines under this SASA is subject to the conditions that:

   a. The pharmacist must have successfully completed the approved course of training relevant to the formulation of buprenorphine depot being administered;

   b. The pharmacy where administration is being conducted must be appropriately equipped to treat patients in the event of an anaphylaxic reaction;

   c. The Pharmacy is authorised as a dosing point under the CPOP;

   d. The patient has a current treatment plan in place with the prescriber and pharmacy that outlines consent to administration by the pharmacist and requirements for communication of dosing issues to the prescriber;

e. The administering pharmacy is the pharmacy nominated to dispense the medicine on the prescription.

f. The original prescription has been presented to the pharmacy prior to administration.

g. Written or documented verbal consent is obtained from the person prior to each instance of administration.

h. All adverse events during or after administration of the buprenorphine depot must be reported to the prescriber and where appropriate to Therapeutic Goods Administration (TGA).

i. A clinical record must be created detailing each administration for the patient. The record must contain:

   1. Patient name and date of birth
   2. Prescriber name
   3. Date of administration
   4. Formulation administered
   5. Dose administered
   6. Site administered
   7. Batch and expiry date of product administered
   8. Name and signature of pharmacist administering

j. Storage and administration are in accordance with Part 9 of the Medicines and Poisons Regulations 2016;

k. Record keeping is in accordance with Part 12 of the Medicines and Poisons Regulations 2016.

5. **References:**
   Community Pharmacotherapy Program available from www.mhc.wa.gov.au/about-us/our-services/community-pharmacotherapy-program/

   CPOP clinical guidelines for the use of depot buprenorphine in the treatment of opioid dependence available from www.mhc.wa.gov.au/media/4651/cpop-clinical-guidelines-for-the-use-of-depot-buprenorphine-in-the-treatment-of-opioid-dependence.pdf

6. **Issued by:**

Name:	Dr Andrew Robertson
Position:	CHIEF HEALTH OFFICER
Date:	13 September 2023

APPENDIX 1

Approved training

All registered pharmacists administering Buprenorphine in accordance with this SASA must have successfully completed:

1. An immunisation course provided by Health Education Services Australia (HESA) or an equivalent course provided by a Registered Training Organisation (RTO) or a university or approved by the Chief Executive Officer of the Department of Health, which provides competency in:
    a. Subcutaneous administration of injections
    b. Obtaining informed consent
    c. Cardiopulmonary resuscitation (CPR)
    d. Diagnosis and management of anaphylaxis
    e. Documentation of administration and critical incidents

    and

2. Community Program for Opioid Pharmacotherapy (CPOP) Pharmacist Online Training provided by Community Pharmacotherapy Program (CPP), Mental Health Commission (MHC).

The Community Program for Opioid Pharmacotherapy (CPOP) Pharmacist Training must be repeated at a minimum of every 3 years.

Pharmacists must maintain competency in both technical administration and knowledge of the buprenorphine depot being administered through relevant continuing professional development and recency of practice for administration of injections.

APPENDIX 2

Approved setting

Registered pharmacists may only administer buprenorphine depot injections in accordance with this SASA at a community pharmacy registered in WA, where:

1. The pharmacy has
    a. A space where administration of an injection can be safely performed, that:
        i. ensures patient privacy and confidentiality;
        ii. permits the patient to lie prone in the event of a severe adverse event or anaphylactic reaction;
        iii. offers unhindered access for emergency staff to attend and perform resuscitation procedures;
    b. An area suitable for direct visual observation of seated patients, for 15 minutes post administration;
    c. Hand washing facilities;
    d. Equipment for disposal of sharps and clinical waste;
    e. An in-date, complete anaphylaxis response kit;
    f. Up-to-date, written procedures covering provision of administration of buprenorphine depot formulations.
2. Has sufficient staffing, during periods of administration to ensure patient safety in post-administration monitoring and adverse event management.